Weight loss drugs may help prevent stroke and reduce complications, studies show
GLP-1 inhibitors linked to reduced mortality and fewer cognitive problems after stroke and brain hemorrhage, according to three studies.
GLP-1s
Employers rethink GLP-1 coverage as costs soar
Prescription drug spending overall increased by 8% last year, with Mercer projecting a 5.8% rise in total health benefit costs for 2025.
Major insurance change hits users of Zepbound for weight loss
Millions of patients using GLP-1 drugs for weight loss could see costs skyrocket.
GNC study shows GLP-1 users at risk of nutritional deficiencies
Research reveals diet deficiencies and potential health risks for patients using popular weight loss drugs.
BOOST Advanced Nutritional Shake provides the nutritional needs of adults on a GLP-1 weight loss journey
BOOST Advanced Nutritional Shakes feature key macro- and micro-nutrients to support nutritional needs during weight loss.
McKinsey: GLP-1s are changing obesity care
GLP-1 medications have emerged as a breakthrough treatment, with prescriptions growing 38 percent annually between 2022 and 2024 and sales expected to reach $100 billion by 2030.
Acosta study shows shopper behavior shifts from GLP-1 use
Retailers are encouraged to merchandise dietary support items near pharmacies, enhance digital shopping tools, and adapt packaging to highlight nutritional benefits clearly.
The Vitamin Shoppe launches supplement line for GLP-1 users
The new supplement range is dietitian-formulated and doctor-approved, providing targeted support across five key categories: protein, fiber, probiotics, multivitamins, and an all-in-one nutrient solution.
Deloitte: GLP-1s drive surge in pharmaceutical R&D returns
GLP-1 therapies emerge as a key driver of industry return on investment.
Compounding pharmacies keep copying Zepbound despite FDA ban
The FDA has yet to comment on how it will proceed. Eli Lilly could pursue legal action against compounding pharmacies.
Olio Labs study shows why women experience more GLP-1 side effects
With the obesity treatment market expected to reach $200 billion by 2031, this study could greatly influence future therapeutic approaches.
Novo Nordisk: FDA confirms end of Wegovy and Ozempic shortage
Novo Nordisk has increased manufacturing, running production facilities 24/7 to ensure steady shipments to wholesalers.
